Personalized therapy for acute myeloid leukemia

Christopher S. Hourigan; Judith E. Karp

doi:10.1158/2159-8290.CD-13-0832

Personalized therapy for acute myeloid leukemia

Christopher S. Hourigan, Judith E. Karp

University Administration

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Patient-specific ex vivo drug sensitivity and resistance screening can identify rational drug candidates for the testing of personalized targeted therapy. An iterative approach of genomic and drug susceptibility characterization at sequential time points during clinical trials of targeted therapy in acute myeloid leukemia may be useful both for characterizing mechanisms of resistance and clonal evolution and also for identification of novel therapeutic targets and drug combinations.

Original language	English (US)
Pages (from-to)	1336-1338
Number of pages	3
Journal	Cancer discovery
Volume	3
Issue number	12
DOIs	https://doi.org/10.1158/2159-8290.CD-13-0832
State	Published - Dec 2013

ASJC Scopus subject areas

Oncology

Access to Document

10.1158/2159-8290.CD-13-0832

Cite this

@article{4b20ef78644845cc8cb4379a9a51ba6e,

title = "Personalized therapy for acute myeloid leukemia",

abstract = "Patient-specific ex vivo drug sensitivity and resistance screening can identify rational drug candidates for the testing of personalized targeted therapy. An iterative approach of genomic and drug susceptibility characterization at sequential time points during clinical trials of targeted therapy in acute myeloid leukemia may be useful both for characterizing mechanisms of resistance and clonal evolution and also for identification of novel therapeutic targets and drug combinations.",

author = "Hourigan, {Christopher S.} and Karp, {Judith E.}",

year = "2013",

month = dec,

doi = "10.1158/2159-8290.CD-13-0832",

language = "English (US)",

volume = "3",

pages = "1336--1338",

journal = "Cancer Discovery",

issn = "2159-8274",

publisher = "American Association for Cancer Research Inc.",

number = "12",

}

TY - JOUR

T1 - Personalized therapy for acute myeloid leukemia

AU - Hourigan, Christopher S.

AU - Karp, Judith E.

PY - 2013/12

Y1 - 2013/12

N2 - Patient-specific ex vivo drug sensitivity and resistance screening can identify rational drug candidates for the testing of personalized targeted therapy. An iterative approach of genomic and drug susceptibility characterization at sequential time points during clinical trials of targeted therapy in acute myeloid leukemia may be useful both for characterizing mechanisms of resistance and clonal evolution and also for identification of novel therapeutic targets and drug combinations.

AB - Patient-specific ex vivo drug sensitivity and resistance screening can identify rational drug candidates for the testing of personalized targeted therapy. An iterative approach of genomic and drug susceptibility characterization at sequential time points during clinical trials of targeted therapy in acute myeloid leukemia may be useful both for characterizing mechanisms of resistance and clonal evolution and also for identification of novel therapeutic targets and drug combinations.

UR - http://www.scopus.com/inward/record.url?scp=84890093892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890093892&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-13-0832

DO - 10.1158/2159-8290.CD-13-0832

M3 - Article

C2 - 24327695

AN - SCOPUS:84890093892

SN - 2159-8274

VL - 3

SP - 1336

EP - 1338

JO - Cancer Discovery

JF - Cancer Discovery

IS - 12

ER -

Personalized therapy for acute myeloid leukemia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this